×
验证码:
换一张
忘记密码?
记住我
CORC
首页
科研机构
检索
知识图谱
申请加入
托管服务
登录
注册
在结果中检索
科研机构
中国医学科学院 北... [21]
吉林大学白求恩第一... [10]
复旦大学上海医学院 [7]
合肥物质科学研究院 [3]
上海药物研究所 [1]
山东大学 [1]
更多...
内容类型
期刊论文 [32]
会议论文 [11]
发表日期
2022 [2]
2021 [1]
2020 [1]
2019 [4]
2018 [14]
2017 [18]
更多...
×
知识图谱
CORC
开始提交
已提交作品
待认领作品
已认领作品
未提交全文
收藏管理
QQ客服
官方微博
反馈留言
浏览/检索结果:
共43条,第1-10条
帮助
已选(
0
)
清除
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
作者升序
作者降序
题名升序
题名降序
发表日期升序
发表日期降序
提交时间升序
提交时间降序
Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
期刊论文
JOURNAL OF CLINICAL ONCOLOGY, 2022, 卷号: 40
作者:
Li, Ning
;
Zhang, Youzhong
;
Wang, Jing
;
Zhu, Jianqing
;
Wang, Li
收藏
  |  
浏览/下载:30/0
  |  
提交时间:2022/12/22
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
期刊论文
CLINICAL CANCER RESEARCH, 2022, 卷号: 28
作者:
Wu, Xiaohua
;
Zhu, Jianqing
;
Wang, Jing
;
Lin, Zhongqiu
;
Yin, Rutie
收藏
  |  
浏览/下载:103/0
  |  
提交时间:2022/03/28
High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer
期刊论文
BREAST CANCER, 2021
作者:
Zhu, Liang
;
Pan, Jia-Ni
;
Qian, Ziliang
;
Ye, Wei-Wu
;
Wang, Xiao-Jia
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2021/09/06
CIN
TP53
BRCA1
LPWGS
Breast cancer
Phase I dose-escalation and expansion study of PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumors
期刊论文
CHINESE JOURNAL OF CANCER RESEARCH, 2020, 卷号: 32, 期号: 3, 页码: 370-+
作者:
Li, Huiping
;
Liu, Rongrui
;
Shao, Bin
;
Ran, Ran
;
Song, Guohong
收藏
  |  
浏览/下载:22/0
  |  
提交时间:2020/12/24
Phase I
PARP inhibitor (fluzoparib)
solid tumor
pharmacokinetics
safety
antitumor activity
Multiple cancer susceptible genes sequencing in BRCA-negative breast cancers with high hereditary risk
会议论文
作者:
Lang, G-T
;
Hu, X.
;
Shao, Z-M
;
Huang, W.
;
Shi, J-X
收藏
  |  
浏览/下载:11/0
  |  
提交时间:2019/12/05
germline mutation
BRCA-negative
hereditary breast cancer
multiple-gene sequencing
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
期刊论文
2019, 卷号: 120, 页码: 20-30
作者:
Robson Mark
;
Ruddy Kathryn J
;
Im Seock-Ah
;
Senkus Elżbieta
;
Xu Binghe
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2020/01/03
BRCA
Breast cancer
EORTC QLQ-C30
Health-related quality of life
Olaparib
OlympiAD
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
期刊论文
2019, 卷号: 30, 期号: 4, 页码: 558-566
作者:
Robson, M. E.
;
Tung, N.
;
Conte, P.
;
Im, S-A
;
Senkus, E.
收藏
  |  
浏览/下载:8/0
  |  
提交时间:2020/01/03
breast cancer
germline BRCA mutation
overall survival
PARP inhibitor
olaparib
tolerability
Germline mutation landscape of Chinese patients with familial breast/ovarian cancer in a panel of 22 susceptibility genes
期刊论文
2019, 卷号: 8, 期号: 5, 页码: 2074-2084
作者:
Wang, Jiayu
;
Li, Weiwei
;
Shi, Yujian
;
Huang, Yan
;
Sun, Tao
收藏
  |  
浏览/下载:28/0
  |  
提交时间:2020/01/03
BRCA1
BRCA2
familial breast cancer
multigenes
novel mutation
Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
会议论文
作者:
Senkus-Konefka, E.
;
Domchek, S. M.
;
Im, S. A.
;
Xu, B.
;
Armstrong, A.
收藏
  |  
浏览/下载:12/0
  |  
提交时间:2019/12/05
Tolerability of olaparib monotherapy versus chemotherapy in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD
期刊论文
CANCER RESEARCH, 2018, 卷号: 78, 期号: 4
作者:
Domchek, Susan M.
;
Robson, Mark
;
Im, Seock-Ah
;
Senkus, Elzbieta
;
Xu, Binghe
收藏
  |  
浏览/下载:3/0
  |  
提交时间:2019/12/05
©版权所有 ©2017 CSpace - Powered by
CSpace